Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

March 18, 2008 09:01 ET

Ambrilia: Conference Call and Webcast for Fiscal 2007 Results and Review of Programs and Milestones

MONTREAL, QUEBEC--(Marketwire - March 18, 2008) - Ambrilia Biopharma Inc. (TSX:AMB) announced today that it will be hosting a conference call and webcast on Tuesday, March 25, 2008, at 9:00 am ET, to discuss the financial results for the fourth quarter and fiscal year ended December 31, 2007, and provide a review of its development programs and milestones. Prior to the conference call, a press release will be issued on Monday, March 24, 2008, after market close. The call will be hosted by Dr. Philippe Calais, President and Chief Executive Officer, Ambrilia, and Ms. Monique Letourneau, Executive Vice-President, Finance and Chief Financial Officer, Ambrilia.

Interested parties may access the conference call by way of telephone or webcast. The numbers to access the conference call are (416) 644-3416 (international) and 1(800) 732-9303 (toll free). The webcast will be available on the Company's website at, Investors' section, Conference calls and webcasts, and will be archived for 365 days.

A replay of the call will be available on the Company's website at, Investors' section, Conference calls and webcasts, from Tuesday, March 25, 2008, 11:00 am ET to Tuesday, April 1, 2008, 11:59 pm ET, and the numbers to access the replay are (416) 640-1917 (international) and 1(877) 289-8525 (toll free) with access code 21265903.


Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. In the latter part of 2007, Ambrilia adopted a new strategic plan, the primary objective of which is to progressively refocus R&D activities solely on antivirals. The strategy aims to capitalize on the Company's broad portfolio and original expertise in virology. Today, Ambrilia's product portfolio comprises of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery platform for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.), HIV integrase inhibitor and entry inhibitor programs, and an HCV polymerase inhibitor program. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site:

Contact Information